Eli Lilly’s AtaiBeckley acquisition marks a dozen M&A deals for the pharma company so far this year. AtaiBeckley’s lead program is an intranasally administered psychedelic drug in pivotal testing for treatment-resistant depression.
The post Lilly Expands Its Mind to Psychedelics With $2.8B AtaiBeckley Acquisition appeared first on MedCity News.
